Patents by Inventor Hye Won AHN

Hye Won AHN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MELANOCORTIN-4 RECEPTOR AGONISTS
    Publication number: 20260092056
    Abstract: The present invention relates to a compound exhibiting excellent agonist activity against melanocortin receptors. More specifically, the present invention relates to a compound of Formula 1, a pharmaceutical composition comprising the compound as an active ingredient, and a use thereof, and the compound of the present invention exhibits excellent agonist activity against melacortin-4 receptors and can be particularly useful in preventing or treating obesity, diabetes, inflammation and erectile dysfunction.
    Type: Application
    Filed: December 5, 2025
    Publication date: April 2, 2026
    Inventors: Seung Wan Kang, Hee Dong Park, Hee Dong Park, Su Jin Yeo, Hyun Seo Park, Ji Ho Hong, Hye Won Ahn, Eun Sil Choi
  • Melanocortin-4 receptor agonists
    Patent number: 12516047
    Abstract: The present invention relates to a compound exhibiting excellent agonist activity against melanocortin receptors. More specifically, the present invention relates to a compound of Formula 1, a pharmaceutical composition comprising the compound as an active ingredient, and a use thereof, and the compound of the present invention exhibits excellent agonist activity against melacortin-4 receptors and can be particularly useful in preventing or treating obesity, diabetes, inflammation and erectile dysfunction.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: January 6, 2026
    Assignee: LG CHEM, LTD.
    Inventors: Seung Wan Kang, Hee Dong Park, Hee Dong Park, Su Jin Yeo, Hyun Seo Park, Ji Ho Hong, Hye Won Ahn, Eun Sil Choi
  • MELANOCORTIN-4 RECEPTOR AGONIST
    Publication number: 20240190856
    Abstract: The present invention relates to a compound showing an excellent agonistic activity for a melanocortin receptor and, more specifically, to the compound of chemical formula 1, a pharmaceutical composition containing same as an active ingredient, and a use thereof. In detail, the compound of the present invention exhibits an excellent agonistic activity for melanocortin-4 receptor and thus, can be advantageously used especially for preventing or treating obesity, diabetes, inflammation, and impotence.
    Type: Application
    Filed: February 25, 2022
    Publication date: June 13, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Eun Sil CHOI, Hee Dong PARK, Seung Wan KANG, Hye Won AHN, Deok Seong PARK
  • USES OF MELANOCORTIN-4 RECEPTOR AGONIST
    Publication number: 20240148743
    Abstract: The present invention relates to uses of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing or treating rare genetic obesity diseases, particularly rare genetic obesity diseases associated with a damaged melanocortin-4 receptor (MC4R) pathway.
    Type: Application
    Filed: January 20, 2022
    Publication date: May 9, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Hee Dong PARK, Su Jin YEO, Hye Won AHN
  • USE AS SELECTIVE AGONIST OF MELANOCORTIN-4 RECEPTOR
    Publication number: 20240091235
    Abstract: The present invention relates to use of a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof as a selective agonist of the melanocortin-4-receptor (MC4R).
    Type: Application
    Filed: December 21, 2021
    Publication date: March 21, 2024
    Applicant: LG CHEM, LTD.
    Inventors: Hee Dong PARK, Su Jin YEO, Hyun Seo PARK, Jin Sook PARK, Hye Won AHN
  • MELANOCORTIN-4 RECEPTOR AGONISTS
    Publication number: 20220289731
    Abstract: The present invention relates to a compound exhibiting excellent agonist activity against melanocortin receptors. More specifically, the present invention relates to a compound of Formula 1, a pharmaceutical composition comprising the compound as an active ingredient, and a use thereof, and the compound of the present invention exhibits excellent agonist activity against melacortin-4 receptors and can be particularly useful in preventing or treating obesity, diabetes, inflammation and erectile dysfunction.
    Type: Application
    Filed: November 6, 2020
    Publication date: September 15, 2022
    Applicant: LG CHEM, LTD.
    Inventors: Seung Wan KANG, Hee Dong PARK, Hee Dong PARK, Su Jin YEO, Hyun Seo PARK, Ji Ho HONG, Hye Won AHN, Eun Sil CHOI